Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib Combinations in TNBC
NCT03800836Phase 1Completed
- Sponsor
- Roche
- Start
- Feb 2018
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of ipatasertib in triple-negative breast cancer (TNBC), sponsored by Roche. Primary endpoints: Objective Response Rate at 43.6 months, Pathological Complete Response Rate at 69 weeks and 1 more. Started Feb 2018; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03800836.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03800836.